The Belgian Diabetes in Pregnancy Study (BEDIP-N), a multi-centric prospective cohort study on screening for diabetes in pregnancy and gestational diabetes: methodology and design

BMC Pregnancy and Childbirth

Chantal Mathieu²  Roland Devlieger²  Katrien De Clippel¹  Farah Mekahli¹  Yves Jacquemyn⁵  Christophe De Block⁵  Els Dufraimont⁴  Chris Vercammen⁴  Hilde Verlaenen³  Sofie Vandeginste⁶  Johan Verhaeghe²  Paul Van Crombrugge³  Katrien Benhalima² 

[1] Department of Endocrinology and Department of Obstetrics & Gynecology, Kliniek St-Jan Brussel, Kruidtuinlaan 32, 1000 Brussel, Belgium;Department of Endocrinology and Department of Obstetrics & Gynecology, UZ Gasthuisberg, KU Leuven, Herestraat 49, 3000 Leuven, Belgium;Department of Endocrinology and Department of Obstetrics & Gynecology, OLV ziekenhuis Aalst-Asse-Ninove, Bloklaan 5, 1730 Asse, Belgium;Department of Endocrinology and Department of Obstetrics & Gynecology, Imelda ziekenhuis, Imeldalaan 9, 2820 Bonheiden, Belgium;Department of Endocrinology and Department of Obstetrics & Gynecology, UZA, Wilrijkstraat 10, 2560 Edegem, Belgium;Department of Endocrinology and Department of Obstetrics & Gynecology, OLV ziekenhuis Aalst-Asse-Ninove, Moorselbaan 164, 9300 Aalst, Belgium

关键词: Diagnostic criteria;    Screening;    Gestational diabetes;    Overt diabetes in pregnancy;   

Others  :  1127173
DOI  :  10.1186/1471-2393-14-226

 received in 2014-06-02, accepted in 2014-07-08,  发布年份 2014

【 摘 要 】

Background

The International Association of Diabetes and Pregnancy Study Groups (IADPSG) recommends universal screening with a 75 g oral glucose tolerance test (OGTT) using stricter criteria for gestational diabetes (GDM). This may lead to important increases in the prevalence of GDM and associated costs, whereas the gain in health is unclear. The goal of ‘The Belgian Diabetes in Pregnancy Study’ (BEDIP-N) is to evaluate the best screening strategy for pregestational diabetes in early pregnancy and GDM in an ethnically diverse western European population. The IADPSG screening strategy will be followed, but in addition risk questionnaires and a 50 g glucose challenge test (GCT) will be performed, in order to define the most practical and most cost effective screening strategy in this population.

Methods

BEDIP-N is a prospective observational cohort study in 6 centers in Belgium. The aim is to enroll 2563 pregnant women in the first trimester with a singleton pregnancy, aged 18–45 years, without known diabetes and without history of bariatric surgery. Women are universally screened for overt diabetes and GDM in the first trimester with a fasting plasma glucose and for GDM between 24–28 weeks using the 50 g GCT and independently of the result of the GCT, all women will receive a 75 g OGTT using the IADPSG criteria. Diabetes and GDM will be treated according to a standardized routine care protocol. Women with GDM, will be reevaluated three months postpartum with a 75 g OGTT. At each visit blood samples are collected, anthropometric measurements are obtained and self-administered questionnaires are completed. Recruitment began in April 2014.

Discussion

This is the first large, prospective cohort study rigorously assessing the prevalence of diabetes in early pregnancy and comparing the impact of different screening strategies with the IADPSG criteria on the detection of GDM later in pregnancy.

Trial registration

ClinicalTrials.gov: NCT02036619. Registered 14-1-2014.

【 授权许可】

   
2014 Benhalima et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2009, 32:S62-S67.
• [2]Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, Hadden DR, McCance DR, Hod M, McIntyre HD, Oats JJ, Persson B, Rogers MS, Sacks DA, HAPO Study Cooperative Research Group: Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008, 358:1991-2002.
• [3]Gilmartin AB, Ural SH, Repke JT: Gestational diabetes mellitus. Rev Obstet Gynecol 2008, 1:129-134.
• [4]Bellamy L, Casas JP, Hingorani AD, Williams D: Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet 2009, 373:1773-1779.
• [5]O’Sullivan JB, Mahan CM: Criteria for oral glucose tolerance test in pregnancy. Diabetes 1964, 13:278-285.
• [6]Metzger BE, Buchanan TA, Coustan DR, de Leiva A, Dunger DB, Hadden DR, Hod M, Kitzmiller JL, Kjos SL, Oats JN, Pettitt DJ, Sacks DA, Zoupas C: Summary and recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes Care 2007, 30(suppl 2):S251-S260.
• [7]Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries W, Robinson JS: Australian Carbohydrate Intolerance study in Pregnancy Women (ACHOIS) Trial Group. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 2005, 352:2477-2486.
• [8]Landon MB, Spong CY, Thom E, Carpenter M, Ramin SM, Casey B, Wapner RJ, Varner MW, Rouse DJ, Thorp JM Jr, Sciscione A, Catalano P, Harper M, Saade G, Lain KY, Sorokin Y, Peaceman AM, Tolosa JE, Anderson GB, Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network: A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med 2009, 361:1339-1348.
• [9]International Association of Diabetes and Pregnancy Study Groups Consensus Panel: International association of diabetes and pregnancy study groups recommendations on the diagnostic and classification of hyperglycemia in pregnancy. Diabetes Care 2010, 33:676-682.
• [10]Lawrence JM, Contreras R, Chen W, Sacks DA: Trends in the prevalence of preexisting diabetes and gestational diabetes mellitus among a racially/ethnically diverse population of pregnant women, 1999–2005. Diabetes Care 2008, 31:899-904.
• [11]Sacks DA, Hadden R, Maresh M, Deerochanawong C, Dyer AR, Metzger BE, Lowe LP, Coustan DR, Hod M, Oats JJ, Persson B, Trimble ER, HAPO Study Cooperative Research Group: Frequency of gestational diabetes mellitus at collaborating centers based on IADPSG consensus panel-recommended criteria. Diabetes Care 2012, 35:526-528.
• [12]Jenum AK, Mǿrkrid K, Sletner L, Vangen S, Torper JL, Nakstad B, Voldner N, Rognerud-Jensen OH, Berntsen S, Mosdøl A, Skrivarhaug T, Vårdal MH, Holme I, Yajnik CS, Birkeland KI: Impact of ethnicity on gestational diabetes identified with the WHO and the modified IADPSG criteria: a population-based cohort study. Eur J Endocrinol 2012, 166:317-324.
• [13]Ryan EA: Diagnosing gestational diabetes. Diabetologia 2011, 54:480-486.
• [14]Waugh N, Pearson D, Royle P: Screening for hyperglycaemia in pregnancy: consensus and controversy. Best Pract Res Clin Endocrinol Metab 2010, 24:553-571.
• [15]Cundy T, Ackermann E, Ryan EA: Gestational diabetes: new criteria may triple the prevalence but effect on outcomes is unclear. BMJ 2014, 11(348):g1567. doi:10.1136/bmj.g1567
• [16]Harlass FE, Brady K, Read JA: Reproducibility of the oral glucose tolerance test in pregnancy. Am J Obstet Gynecol 1991, 164:564-568.
• [17]Werner EF, Petther CM, Zuckerwise L, Reel M, Funai EF, Henderson J, Thung SF: Screening for gestational diabetes mellitus: are the criteria proposed by the International Association of Diabetes and Pregnancy Study Groups cost-effective? Diabetes Care 2012, 35:529-535.
• [18]Mission JF, Ohno MS, Cheng YW, Caughey AB: Gestational diabetes screening with new IADPSG guidelines: a cost-effectiveness analysis. Am J Obstet Gynecol 2012, 207:326e1-326e9.
• [19]Committee on Obstetric Practice Screening and diagnosis of gestational diabetes mellitus Obstet Gynecol 2011, 118:751-753.
• [20]Vandorsten JP, Dodson WC, Espeland MA, Grobman WA, Guise JM, Mercer BM, Minkoff HL, Poindexter B, Prosser LA, Sawaya GF, Scott JR, Silver RM, Smith L, Thomas A, Tita AT: NIH Consensus Development Conference: Diagnosing Gestational Diabetes Mellitus. NIH Consensus State Sci Statements 2013, 29:1-31.
• [21]The World Health Organization guideline 2013: Diagnostic criteria and classification of hyperglycaemiafirstdetectedinpregnancy. [http://apps.who.int/iris/bitstream/10665/85975/1/WHO_NMH_MND_13.2_eng.pdf webcite]. Accessed on 17-11-2013
• [22]Blumer I, Hadar E, Hadden DR, Jovanovič L, Mestman JH, Murad MH, Yogev Y: Diabetes and pregnancy: an endocrine society clinical practice guideline. JCEM 2013, 98:4227-4249.
• [23]American Diabetes Association: Standards of Medical Care in diabetes-2014. Diabetes Care 2014, 37:S14-S80.
• [24]Benhalima K, Van Crombrugge P, Devlieger R, Verhaeghe J, Verhaegen A, De Catte L, Mathieu C: Screening for pregestational and gestational diabetes in pregnancy: a survey of obstetrical centers in the northern part of Belgium. Diabetol Metab Syndr 2013, 5:66. doi:10.1186/1758-5996-5-66
• [25]Benhalima K for the VDV-VVOG-Domus Medica consensus group: The VDV-VVOG-Domus Medica consensus 2012 on screening for pregestational diabetes in pregnancy and screening for gestational diabetes. P Belg Roy Acad Med 2013, 2:24-42.
• [26]Vanderijst J-F, Debieve F, Doucet F, Emonts P, Haumont S, Hubinont C, Kirkpatrick C, Philips JC, Pintiaux A, Rousseau P, Senterre G, Vandeleene B, Féry F, Groupement des Gynécologues Obstétriciens: Stratégie de dépistage et critères diagnostiques du diabète gestationnel. Propositions du GGOLFB. Rev Med Liege 2012, 67(4):179-185.
• [27]Lapolla A, Dalfra MG, Ragazzi E, De Cata AP, Fedele D: New International Association of the Diabetes and Pregnancy Study Groups (IADPSG) recommendations for diagnosing gestational diabetes compared with former criteria: a retrospective study on pregnancy outcome. Diabet Med 2011, 28:1074-1077.
• [28]O’Sullivan EP, Avalos G, O’Reilly M, Dennedy MC, Gaffney G, Dunne F, Atlantic DIP collaborators: Atlantic Diabetes in Pregnancy (DIP): the prevalence and outcomes of gestational diabetes mellitus using new diagnostic criteria. Diabetologia 2011, 54:1670-1675.
• [29]Benhalima K, Hanssens M, Devlieger R, Verhaeghe J, Mathieu C: Analysis of pregnancy outcomes using the new IADPSG recommendation compared with the Carpenter and Coustan criteria in an area with a low prevalence of gestational diabetes. Int J Endocrinology 2013, 1:1. doi:10.1155/2013/248.121
• [30]Benhalima K, Van Crombrugge P, Hanssens M, Devlieger R, Verhaeghe J, Mathieu C: Gestational diabetes: overview of the new consensus screening strategy and diagnostic criteria. Acta Clin Belg 2012, 67:255-261.
• [31]Agarwal MM, Dhatt GS, Shah SM: Gestational diabetes mellitus. Simplifying the International Association of Diabetes and Pregnancy diagnostic algorithm using fasting plasma glucose. Diabetes Care 2010, 33:2018-2020.
• [32]Duran A, Matin P, Runkle I, Pérez N, Abad R, Fernández M, Del Valle L, Sanz MF, Calle-Pascual AL: Benefits of self-monitoring blood glucose in the management of new-onset type 2 diabetes mellitus: the St Carlos Study, a prospective randomized clinic-based interventional study with parallel groups. J Diabetes 2010, 2:203-2011.
• [33]Harrison CL, Thompson RG, Teede HJ, Lombard CB: Measuring physical activity during pregnancy. Int J Behav Nutr Phys Act 2011, 8:19. doi:10.1186/1479-5868-8-19
• [34]Dalfrà MG, Nicolucci A, Bisson T, Bonsembiante B, Lapolla A: Quality of life in pregnancy and post-partum: a study in diabetic patients. Qual Life Res 2012, 21:291-298.
• [35]Petrou S, Morrell J, Spiby H: Assessing the empirical validity of alternative multi-attribute utility measures in the maternity context. Health Qual Life Out 2009, 7:40-52.
• [36]Sibai BM: The HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): much ado about nothing? Am J Obstet Gynaecol 1990, 162:311-316.
• [37]Matsuda M, Defronzo RA: Insulin sensitivity indices obtained from oral glucose tolerance testing. Comparison with the euglycemic insulin clamp. Diabetes Care 1999, 22:1462-1470.
• [38]Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostais model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
• [39]Kahn SE: The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003, 43:3-19.
• [40]The Diabetes Prevention Program Research Group: Role of insulin secretion and sensitivity in the evolution of diabetes type 2 in the Diabetes Prevention Program: effects of lifestyle intervention and metformin. Diabetes 2005, 54:2404-2414.
• [41]Kirwan JP, Huston-Presley L, Kalhan SC, Catalano PM: Clinically useful estimates of insulin sensitivity during pregnancy: validation studies in women with normal glucose tolerance and gestational diabetes. Diabetes Care 2001, 24:1602-1607.
• [42]Retnakaran R, Qi Y, Goran MI, Hamilton JK: Evaluation of proposed oral disposition index measures in relation to the actual disposition index. Diabet Med 2009, 26:1198-1203.
• [43]Bouillon R, Van HE, Jans I, Tan BK, Van Baelen H, De Moor P: Two direct (nonchromatographic) assays for 25-hydroxyvitamin D. Clin Chem 1984, 30:1731-1736.
• [44]Toulis KA, Stagnaro-Green A, Negro R: Maternal Subclinical Hypothyroidsm and Gestational Diabetes Mellitus: A Meta Analysis. Endocr Practice 2014, 21:1-18.
• [45]Vermeulen I, Weets I, Costa O, Asanghanwa M, Verhaeghen K, Decochez K, Ruige J, Casteels K, Wenzlau J, Hutton JC, Pipeleers DG, Gorus FK, Belgian Diabetes Registry: An important minority of prediabetic first-degree relatives of type 1 diabetic patients derives from seroconversion to persistent autoantibody positivity after 10 years of age. Diabetologia 2012, 55:413-420.
• [46]The HAPO, Study Cooperative Research Group: Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study. Associations with neonatal anthropometrics. Diabetes 2009, 58:453-459.
• [47]Institute of Medicine (US) and National Research Council (US) Committee to Reexamine IOM Pregnancy Weight Guidelines: Weight Gain During Pregnancy: Reexamining the Guidelines. In National Academies Press (US). Edited by Rasmussen KM, Yaktine AL. Washington (DC): The National Academies Collection: Reports funded by National Institutes of Health; 2009.